These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
78 related articles for article (PubMed ID: 12565780)
21. No association of the 5' promoter region polymorphism of CYP17 gene with prostate cancer risk. dos Santos A; Ribeiro ML; Mesquita JC; Carvalho-Salles AB; Hackel C Prostate Cancer Prostatic Dis; 2002; 5(1):28-31. PubMed ID: 15195127 [TBL] [Abstract][Full Text] [Related]
22. Pro-(IL-18) and Anti-(IL-10) Inflammatory Promoter Genetic Variants (Intrinsic Factors) with Tobacco Exposure (Extrinsic Factors) May Influence Susceptibility and Severity of Prostate Carcinoma: A Prospective Study. Dwivedi S; Singh S; Goel A; Khattri S; Mandhani A; Sharma P; Misra S; Pant KK Asian Pac J Cancer Prev; 2015; 16(8):3173-81. PubMed ID: 25921117 [TBL] [Abstract][Full Text] [Related]
23. Molecular and Clinicopathological Aspects of Prostate Cancer in Bulgarian Probands. Tsvetkova A; Todorova A; Todorov T; Georgiev G; Drandarska I; Mitev V Pathol Oncol Res; 2015 Sep; 21(4):969-76. PubMed ID: 25753984 [TBL] [Abstract][Full Text] [Related]
24. Microsatellite polymorphism of steroid hormone synthesis gene CYP11A1 is associated with advanced prostate cancer. Kumazawa T; Tsuchiya N; Wang L; Sato K; Kamoto T; Ogawa O; Nakamura A; Kato T; Habuchi T Int J Cancer; 2004 May; 110(1):140-4. PubMed ID: 15054879 [TBL] [Abstract][Full Text] [Related]
25. The novel tumor-suppressor Mel-18 in prostate cancer: its functional polymorphism, expression and clinical significance. Wang W; Yuasa T; Tsuchiya N; Ma Z; Maita S; Narita S; Kumazawa T; Inoue T; Tsuruta H; Horikawa Y; Saito M; Hu W; Ogawa O; Habuchi T Int J Cancer; 2009 Dec; 125(12):2836-43. PubMed ID: 19585577 [TBL] [Abstract][Full Text] [Related]
26. Boron intake, osteocalcin polymorphism and serum level in postmenopausal osteoporosis. Boyacioglu O; Orenay-Boyacioglu S; Yildirim H; Korkmaz M J Trace Elem Med Biol; 2018 Jul; 48():52-56. PubMed ID: 29773193 [TBL] [Abstract][Full Text] [Related]
27. Insulin-like growth factor-binding protein-3 gene -202 A/C polymorphism is correlated with advanced disease status in prostate cancer. Wang L; Habuchi T; Tsuchiya N; Mitsumori K; Ohyama C; Sato K; Kinoshita H; Kamoto T; Nakamura A; Ogawa O; Kato T Cancer Res; 2003 Aug; 63(15):4407-11. PubMed ID: 12907612 [TBL] [Abstract][Full Text] [Related]
28. Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways. Latil AG; Azzouzi R; Cancel GS; Guillaume EC; Cochan-Priollet B; Berthon PL; Cussenot O Cancer; 2001 Sep; 92(5):1130-7. PubMed ID: 11571725 [TBL] [Abstract][Full Text] [Related]
29. Association between genetic polymorphisms in the prostate-specific antigen gene promoter and serum prostate-specific antigen levels. Cramer SD; Chang BL; Rao A; Hawkins GA; Zheng SL; Wade WN; Cooke RT; Thomas LN; Bleecker ER; Catalona WJ; Sterling DA; Meyers DA; Ohar J; Xu J J Natl Cancer Inst; 2003 Jul; 95(14):1044-53. PubMed ID: 12865450 [TBL] [Abstract][Full Text] [Related]
30. I105V polymorphism and promoter methylation of the GSTP1 gene in prostate adenocarcinoma. Jerónimo C; Varzim G; Henrique R; Oliveira J; Bento MJ; Silva C; Lopes C; Sidransky D Cancer Epidemiol Biomarkers Prev; 2002 May; 11(5):445-50. PubMed ID: 12010858 [TBL] [Abstract][Full Text] [Related]
31. CDKN1B V109G polymorphism frequency and prostate cancer risk in Taiwan. Huang SP; Yu CC; Liu CC; Wu TT; Huang CH; Wu MT Urol Int; 2008; 81(1):36-40. PubMed ID: 18645269 [TBL] [Abstract][Full Text] [Related]
32. Prostate-specific antigen and 17-hydroxylase polymorphic genotypes in patients with prostate cancer and benign prostatic hyperplasia. Gunes S; Bagci H; Sarikaya S; Bilen CY; Kara N DNA Cell Biol; 2007 Dec; 26(12):873-8. PubMed ID: 17961073 [TBL] [Abstract][Full Text] [Related]
33. The -786T>C promoter polymorphism of the NOS3 gene is associated with prostate cancer progression. Marangoni K; Araújo TG; Neves AF; Goulart LR BMC Cancer; 2008 Sep; 8():273. PubMed ID: 18823560 [TBL] [Abstract][Full Text] [Related]
34. CYP17 polymorphisms in relation to risks of prostate cancer and benign prostatic hyperplasia: a population-based study in China. Madigan MP; Gao YT; Deng J; Pfeiffer RM; Chang BL; Zheng S; Meyers DA; Stanczyk FZ; Xu J; Hsing AW Int J Cancer; 2003 Nov; 107(2):271-5. PubMed ID: 12949806 [TBL] [Abstract][Full Text] [Related]
35. Osteocalcin gene polymorphism and bone density in Hungarian athletes. Bosnyák E; Trájer E; Protzner A; Komka Z; Györe I; Szmodis M; Tóth M Anthropol Anz; 2016; 73(2):. PubMed ID: 27000019 [TBL] [Abstract][Full Text] [Related]
36. Cyp17 genetic polymorphism in prostate cancer and benign prostatic hyperplasia. Tigli H; Yazici H; Dalay N Res Commun Mol Pathol Pharmacol; 2003; 113-114():307-14. PubMed ID: 15686129 [TBL] [Abstract][Full Text] [Related]
37. Polymorphism of the SRD5A2 gene and the risk of prostate cancer. Dušenka R; Tomaškin R; Kliment J; Dobrota D; Dušenková S; Vilčková M; Sivoňová MK Mol Med Rep; 2014 Dec; 10(6):3151-6. PubMed ID: 25310105 [TBL] [Abstract][Full Text] [Related]
38. Polymorphism of GSTM1 and GSTT1 genes in prostate cancer: a study from North India. Mittal RD; Srivastava DS; Mandhani A; Kumar A; Mittal B Indian J Cancer; 2004; 41(3):115-9. PubMed ID: 15472409 [TBL] [Abstract][Full Text] [Related]
39. Apolipoprotein E Genotypes in Patients with Prostate Cancer. Yencilek F; Yilmaz SG; Yildirim A; Gormus U; Altinkilic EM; Dalan AB; Bastug Y; Turkmen S; Turkan S; Isbir T Anticancer Res; 2016 Feb; 36(2):707-11. PubMed ID: 26851028 [TBL] [Abstract][Full Text] [Related]
40. Polymorphisms in tumor necrosis factor-A gene and prostate cancer risk in North Indian cohort. Kesarwani P; Mandhani A; Mittal RD J Urol; 2009 Dec; 182(6):2938-43. PubMed ID: 19846139 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]